By Peter J. Neumann, Jennifer A. Palmer, Eric Nadler, ChiHui Fang, and Peter Ubel Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists ABSTRACT A national survey of medical oncologists indicates that rising cancer treatment costs are influencing clinical practice, even as oncologists tend not to communicate with patients about costs. The survey shows that 84 percent of oncologists say that patients' out-ofpocket spending influences treatment recommendations. Only 43 percent always or frequently discuss costs with patients. Among those surveyed, 79 percent favor more comparative effectiveness research; 80 percent support more cost-effectiveness data, although only 42 percent feel well prepared to interpret it. The results suggest that physicians support federally funded comparative effectiveness research but that they wish to retain a central role in making decisions about how and when to use expensive cancer treatments. The results also support educating physicians about cost-effectiveness and how to communicate with patients regarding cost. N ew cancer medications offer hope to patients with terminal illnesses. Yet spending on cancer medications has risen 14 percent annually in recent years 1 and can total tens of thousands of dollars per year for some patients. Out-of-pocket spending for cancer patients has been increasing sharply, especially for low-income people, who spend about 27 percent of their yearly income on such expenses.
2,3 When confronted with the reality of high out-of-pocket expenses, patients may forgo expensive therapies or discontinue treatments, in part because they do not want to saddle their families with unmanageable debt.
2,4
The merits of expensive new cancer treatments are debated in the medical literature and the popular news media. [4] [5] [6] The debates focus not only on the costs of these treatments, but also on their relatively modest benefits, which are often on the order of a few weeks or months of increased life expectancy.
Oncologists are positioned in the middle of these debates, forced to decide whether the cost of treatment, to the patient and to society overall, is justified by the benefit. Despite this, little is known about their attitudes toward cancer costs, their beliefs about whether costs influence their prescribing, and their comfort and readiness to make such decisions. We conducted a national survey of U.S. oncologists to investigate these issues.
Study Data And Methods
THE SURVEY We developed a questionnaire to assess oncologists' attitudes toward various aspects of cancer costs and the cost-effectiveness of treatments. We also assessed oncologists' views regarding potential policies related to cost sharing and to the use of comparative effectiveness and cost-effectiveness information.
The survey required approximately fifteen minutes to complete. Respondents were assured of anonymity and confidentiality. All appropriate institutional review board arrangements were met. The survey stated that the research was being conducted by university-affiliated researchers and was sponsored by a nonprofit foundation. In terms of cost-effectiveness, 58 percent stated that patients should have access to effective cancer treatment only if the treatments are costeffective or provide good value for money. With respect to what respondents consider a reasonable definition of "good value for money," the most popular response (49 percent) was $50,001-$100,000 per life-year gained (Exhibit 2).
11 However, only 42 percent said that they feel well prepared to interpret and use information about cost-effectiveness in their treatment decisions. Forty-three percent of respondents said that they always or frequently discuss cancer treatment costs with their patients, while 37 percent said they do so occasionally and 20 percent, said rarely or never.
ATTITUDES ABOUT GOVERNMENT POLICIES Most oncologists (64 percent) agreed with the statement that Medicare reimbursement rules for oral chemotherapy limit their ability to offer these therapies to their patients.
12 Twenty-nine percent stated their belief that more cost sharing by patients is needed. Respondents generally believed that more government intervention is warranted in cancer care. Fifty-seven percent agreed that more government price controls for cancer drugs for Medicare are needed; 79 percent favored more government research on the comparative effectiveness of cancer drugs (Exhibit 3). Eighty percent favored more use of costeffectiveness data in coverage and payment decisions for cancer drugs.
In terms of who they believe should determine whether a drug provides good value for money, most respondents said that physicians (60 percent) followed by nonprofit organizations (57 percent), patients (37 percent), government (21 percent), and insurance companies (6 percent) (choices were not mutually exclusive; Exhibit 3).
13

Discussion
In the face of rapidly rising treatment costs, the majority of U.S. oncologists who responded to our survey indicate that such costs are influencing their clinical practice. At the same time, they often feel ill-equipped to interpret and use economic information when making clinical deci- sions. The oncologists we surveyed believe doctors should play an important role in making decisions about how and when to use expensive cancer treatments. Yet many also want the government to play a more active role in determining the appropriate way to use these therapies.
THE CENTRALITY OF COSTS AS A MODERN-DAY CON-
CERN Our study underscores the importance of cancer treatment costs as a discomforting reality among U.S. oncologists. Other surveys report a similar sense of discomfort and unease in the oncology community, as physicians struggle with their professional roles to balance the needed care and the limited resources of their patients and society. In a survey of ninety academic medical oncologists in Boston, Eric Nadler and colleagues reported similarly high percentages of respondents who stated that out-of-pocket expenses influence their decisions, while maintaining that all patients should have access to effective treatments. 14 Deborah Schrag and Morgan Hanger, 15 reporting on a survey of 167 oncologists, found that most oncologists believe it important to be explicit with patients about costs but that only 16 percent acknowledge omitting treatment because of costs.
THE NEED FOR BETTER COMMUNICATION BETWEEN
PHYSICIANS AND PATIENTS Despite their concern over cost, relatively few oncologists state that they discuss the costs of new cancer treatments with their patients. This finding mirrors other research on the topic. Researchers report that oncologists-and physicians in general-believe that communication is important. They also report that patients desire to talk with their physicians about out-of-pocket expenses, but that such conversations remain uncommon.
15-17
Why don't physicians and patients discuss cost more often? We suspect that most physicians are uncomfortable with the subject. The lack of communication may also reflect an absence of accurate knowledge about the actual costs and the extent of insurance coverage for drugs. 18 Physicians also report having insufficient time to discuss costs with patients, and a belief that they do not have a solution to offer them. 15, 19 Possibly, the lack of communication reflects oncologists' sense that most patients are well insured for the costs of their cancer care. However, rising patient cost-sharing requirements, caps on benefits, and loss of employment opportunities because of patient illness make it less likely that this is always true. 20, 21 Other research finds that patients are reluctant to raise the issue of cost because they feel awkward addressing the topic and have concerns about how discussing cost might affect on quality of care.
2,19
These findings underscore the need to educate physicians about treatment costs, patients' circumstances, and patients' values and the need to explore and implement communication strategies. 15, 18, 19, 22 Importantly, recent initiatives by patient advocacy organizations and oncologists' professional organizations have begun to develop strategies to guide physicians and patients in communicating about cost. These include the [23] [24] [25] SUPPORT FOR COMPARATIVE EFFECTIVENESS RE-SEARCH Our survey reveals frustration among oncologists with the status quo and a willingness to experiment with various policy solutions. A majority of respondents favor government pricecontrol authority for Medicare.
Moreover, most respondents support the idea of more research on the comparative effectiveness of cancer therapies. The results suggest that federally funded comparative effectiveness research will be received favorably in the oncology community. This finding has special relevance in light of the recent American Recovery and Reinvestment Act, which provides $1.1 billion to fund comparative effectiveness research, and in light of provisions of health reform legislation that would expand the research even further. 26 Although the survey responses represent the viewpoints of only one group of physicians, they do suggest some lessons for policymakers in how to frame comparative effectiveness research. For one, they suggest that although oncologists favor a strong role for government in providing analyses, they believe that physicians-and to a lesser extent patients-should retain decisionmaking authority in deciding whether individual drugs should be used.
For another, the results support more costeffectiveness research. Once again, however, they highlight that oncologists believe the government's role should involve providing research findings but should stop short of mandating decisions. Although a large majority of oncologists support cost-effectiveness research, only a small minority support a government role in deciding what care constitutes good value for money. Some other surveys find evidence of support among physicians for cost-effectiveness information. 27 Schrag and Hanger 15 report, for example, that two-thirds of oncologists agree that part of the oncologist's role when making recommendations is to consider cost-effectiveness. Perhaps these results, along with ours, reflect a sign of growing support for cost-effectiveness analysis, especially with the advent of expensive drugs with relatively modest benefits. There have been increasing calls for oncologists to avoid treating all cancer therapies as equally necessary but instead to weigh relative value. [28] [29] [30] [31] In some countries, such as the United Kingdom, health authorities have recommended against certain cancer drugs on the grounds that the drugs are not costeffective. [32] [33] [34] It is unclear who would determine value in the United States, although our survey revealed support among oncologists for a nonprofit institute.
Limitations
Our study has a number of limitations. Although the response rate was high for surveys of this kind, it raises some questions about the representativeness of the sample. Oncologists who chose to respond to our survey may be different from those who did not, although it is not obvious what form the bias would take. In addition, ASCO-affiliated oncologists, who constituted the sample, might not be entirely representative of practicing U.S. oncologists. 35 The Road Ahead Until now, a mentality has persisted among drug companies that they can charge tens of thousands of dollars per year for drugs because the market will bear it, regardless of the degree of patient response or the type of cancer. 36 To an unknown extent, the recent economic slowdown, as well as future competition among drug firms, may drive down prices. 4 Already some biopharmaceutical companies are placing caps on spending for cancer drugs at $55,000 per patient a year, or are limiting expenses to some percentage (such as 5 percent) of a patient's gross income. 37, 38 Payers, including the Medicare program, are implementing "coverage with evidence development" policies, requiring patients to participate in clinical trials or registries to help ensure that expensive drugs are delivered only to appropriate patients. 36 In recent years, Congress changed the way Medicare reimbursed physicians for chemotherapy drugs in an attempt to remove incentives for physicians to provide aggressive and costly treatments and to instill incentives for them to make choices based more on clinical considerations and patients' preferences. 39 Other changes for Medicare are under way or under discussion, from moving away from separate billing for each individual service to increasing the focus on the quality of care provided under the program. 40 Oncologists clearly feel ill prepared to sort out cost issues on their own. It will be important to resurvey oncologists over time as changes are implemented, and to study the attitudes of patients, not just of physicians. ▪ 
